Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries

NCT06887972 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT06887972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 4
Overall status
Completed
Start date
March 21, 2025
Completion date
November 7, 2025
Enrollment
100 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute pain